UY25089A1 - Vacunas no acuosas - Google Patents

Vacunas no acuosas

Info

Publication number
UY25089A1
UY25089A1 UY25089A UY25089A UY25089A1 UY 25089 A1 UY25089 A1 UY 25089A1 UY 25089 A UY25089 A UY 25089A UY 25089 A UY25089 A UY 25089A UY 25089 A1 UY25089 A1 UY 25089A1
Authority
UY
Uruguay
Prior art keywords
solvent
polar
group
nonaqueous
immunogenic polypeptide
Prior art date
Application number
UY25089A
Other languages
English (en)
Inventor
Hungerford James
Albrecht Mark
Original Assignee
Hoechst Roussel Vet Gmbh
Biotech Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO7791A external-priority patent/AUPO779197A0/en
Priority claimed from AUPO7792A external-priority patent/AUPO779297A0/en
Application filed by Hoechst Roussel Vet Gmbh, Biotech Australia Pty Ltd filed Critical Hoechst Roussel Vet Gmbh
Publication of UY25089A1 publication Critical patent/UY25089A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulación de vacuna no acuosa de fase única que contiene un polipéptido inmunogénico disuelto en un solvente polar no acuoso. La formulación también puede contener adyuvantes y/o composiciones farmacéuticas que puedan administrarse conjuntamente con el polipéptido inmunogénico. Se relevan métodos para preparar dicha formulación de vacuna y se proporcionan métodos para utilizar las formulaciones a fin de prevenir y tratar enfermedades de mamíferos. El polipéptido inmunogénico proviene de un organismo parásito, preferentemente de un organismo seleccionado del grupo compuesto por los nematodos y los insectos. En una realización preferida, el solvente no acuoso comprende dimetilsulfóxido (DMSO),si bien pueden utilizarse también otros solventes polares no acuosos. En su forma más conveniente, el DMSO comprende de hasta un 6% de solvente no acuoso, y el resto comprende un solvente hidroxílico polar. El solvente hidroxílico polar se selecciona del grupo integrado por el glicerol formol y el propilén glicol, ó una mezcla de los mismos. En particular, las formulaciones de la presente invención pueden almacenarse durante períodos prolongados a temperaturas ambientes de hasta 40sC aproximadamente sin perder eficacia, es decir, la capacidad de inducir una respuesta inmune protectora. La presente invención es particularmente útil para la administración conjunta de sustancias farmacéuticas que son inestables en solución acuosa, como ser un compuesto antihelmíntico y de manera más preferida es una lactona marcocíclica del grupo de compuestos integrados por la avermectina y la milbemicina.
UY25089A 1997-07-10 1998-07-10 Vacunas no acuosas UY25089A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO7791A AUPO779197A0 (en) 1997-07-10 1997-07-10 Novel vaccines
AUPO7792A AUPO779297A0 (en) 1997-07-10 1997-07-10 Novel vaccines

Publications (1)

Publication Number Publication Date
UY25089A1 true UY25089A1 (es) 2000-08-21

Family

ID=25645460

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25089A UY25089A1 (es) 1997-07-10 1998-07-10 Vacunas no acuosas

Country Status (3)

Country Link
AR (1) AR013202A1 (es)
UY (1) UY25089A1 (es)
WO (1) WO1999002182A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27412A1 (es) * 2002-08-12 2003-06-30 Carlson Internat Inc Un nuevo producto para el combate de garrapatas y el proceso para la prepaacinn.
EP2461677A4 (en) * 2009-08-04 2014-01-08 Genentech Inc CONCENTRATED POLYPEPTIDE FORMULATIONS WITH REDUCED VISCOSITY
US9101557B2 (en) 2011-04-13 2015-08-11 Auburn University Combination of protein forms for hornfly vaccination

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711602A (en) * 1970-10-30 1973-01-16 Crown Zellerbach Corp Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
US4853372A (en) * 1983-12-22 1989-08-01 Merck & Co., Inc. Non-aqueous ivermectin formulation with improved antiparasitic activity
NZ210505A (en) * 1983-12-22 1988-06-30 Merck & Co Inc Parasiticidal compositions containing avermectin or milbemycin derivatives
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
ES2174027T3 (es) * 1995-06-30 2002-11-01 American Cyanamid Co Composiciones estables que contienen macrolidos y macrolidos combinados con unas vacunas.

Also Published As

Publication number Publication date
WO1999002182A3 (en) 1999-04-01
AR013202A1 (es) 2000-12-13
WO1999002182A2 (en) 1999-01-21

Similar Documents

Publication Publication Date Title
ES2174027T3 (es) Composiciones estables que contienen macrolidos y macrolidos combinados con unas vacunas.
ES2184079T3 (es) Agentes para la lucha contra insectos y acaros parasitantes en seres humanos.
ES2142798T3 (es) Derivados de 3-amido pirazol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
CY1114631T1 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
PE20070715A1 (es) Derivados de pirazina
ATE398997T1 (de) Selbst-nanoemulgierende ölige formulierung zur verabreichung von schwer wasserlöslichen arzneimitteln
MY116296A (en) Cosmetic compositions with dbs and functionalized silicones
HN2003000184A (es) Preparaciones acidas de insulina con estabilidad mejorada
ES2233566T3 (es) Composiciones de liberacion prolongada para la adminsitracion parenteral de macrolitos.
PT1206189E (pt) Formulacoes para vacinas de rotavirus
DK164772C (da) Endo- og ectoparasiticidt parenteralt praeparat indeholdende en avermectin- eller milbemycinforbindelse og fremgangsmaade til fremstilling deraf
CL2004001255A1 (es) Formulacion liquida herbicida que contiene (a) uno o mas derivados de acidos policarboxilicos y (b) uno o mas compuestos activos inhibidores de als, procedimiento de para preparar la formulacion que comprende el mezclado de los componentes y metodo p
ES2205926T3 (es) Metodo de produccion de vacunas inactivas asociadas con una emulsion de agua en aceite adyuvante.
DK0525307T3 (da) Stabile præparater til parenteral indgivelse og deres anvendelse
UY25089A1 (es) Vacunas no acuosas
PE20220593A1 (es) Composiciones comprimidas de macitentan, metodos y usos de las mismas
AR037138A1 (es) Formulacion farmaceutica, uso de fulvestrant en la preparacion de la misma y jeringa o vial esteriles que comprenden dicha formulacion
MX9307991A (es) Analogos de insulina, procedimiento para su preparacion y formulaciones farmaceuticas que los incluyen.
ES2204958T3 (es) Compuesto de oxitetraciclina de largo efecto.
BR0108455A (pt) Composição cosmética de uma fase, transparente
CO5670325A2 (es) Uso de aminoacidos basicos en formulaciones fungicidas que contienen cobre
FI913034A0 (fi) Foerening med magsyrainhiberande effekt och foerfarande foer dess framstaellning.
ATE247970T1 (de) Tierärztliche zusammensetzungen zur behandlung von parasiterkrankungen
ES2040774T3 (es) Procedimiento para la preparacion de una formulacion medicamentosa.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20121206